IVA

Inventiva

IVA

Market cap $738M

Overview Fund Activity

5.31 USD

0.00

0%

At close Updated Sep 16, 11:04 AM EDT

1 day

0%

5 days

-5.85%

1 month

15.69%

3 months

58.04%

6 months

86.32%

Year to date

148.13%

1 year

140.27%

5 years

-52.97%

10 years

-60.43%

About: Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Employees: 118

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

50% more funds holding

Funds holding: 8 [Q1] → 12 (+4) [Q2]

28% more capital invested

Capital invested by funds: $12.2M [Q1] → $15.7M (+$3.45M) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

1.54% less ownership

Funds ownership: 5.08% [Q1] → 3.54% (-1.54%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$13

145% upside

Avg. target

$19.67

270% upside

High target

$26

390% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Ananda Ghosh	$20	Buy Assumed	3 Sep 2025
Guggenheim Etzer Darout	$13	Buy Maintained	2 Sep 2025
Piper Sandler Yasmeen Rahimi	$26	Overweight Initiated	27 Aug 2025

See Analyst Rankings

Financial journalist opinion

Inventiva to Participate in Upcoming September Investor Conferences

Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company's leadership will participate in the following upcoming investor events:

Inventiva to Participate in Upcoming September Investor Conferences

Zacks Investment Research

How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%

The mean of analysts' price targets for Inventiva (IVA) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79%

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. The conference is being held from August 12-14, 2025, at the InterContinental Hotel in Boston, Massachusetts. During the fireside chat, Drs. Campagna and Nikodem will highlight recent corporate updates, progress on lanifibranor and the Phase III NATiV3 trial in MASH and discuss the Company's broader R&D strategy and outlook.

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

Inventiva receives $10 million milestone payment from CTTQ

Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of Sino Biopharm. This milestone payment follows the successful settlement of the second tranche of €115.6 million1 in gross proceeds (net proceeds of €108.5 million) of the previously announced structured financing of up to €348 million2 (the “Structured Financing”). In September 2022, Inventiva entered into a licensing and collaboration agreement with CTTQ (as amended on October 11, 2024, the “CTTQ License Agreement”) to develop and commercialize lanifibranor, Inventiva's proprietary compound, for the treatment of MASH and potentially other metabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan. Under the CTTQ License Agreement, Inventiva is eligible to receive up to an additional $265 million of clinical, regulatory and commercial milestone payments, as well as royalties in the low single digits on annual net sales of lanifibranor, if approved. Based on the results from the Phase 2b NATIVE clinical trial, lanifibranor was granted Breakthrough Therapy Designation for MASH by the U.S. Food and Drug Administration in October 2020 and by the Chinese National Medical Products Administration (NMPA) in December 2023. This designation could potentially accelerate the development and regulatory review of drug candidates for serious or life-threatening conditions. CTTQ joined Inventiva's ongoing NATiV3 pivotal Phase 3 clinical trial, which includes over 60 sites across mainland China. Furthermore, CTTQ has completed a Phase I bridging study and confirmed no significant ethnic differences, thereby paving the way to seek regulatory approval in China based on the results of the NATiV3 trial.

Inventiva receives $10 million milestone payment from CTTQ

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

Daix (France), New York City (New York, United States), July 2, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces the publication in Journal of Hepatology Reports, a peer-reviewed, scientific journal, of results from the Phase 2b NATIVE clinical trial and preclinical study evaluating the effects of lanifibranor on liver sinusoidal endothelial cells in Metabolic dysfunction-associated steatotic liver disease (“MASLD”) and MASH.

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

Zacks Investment Research

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

Inventiva (IVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock?

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025.

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

Inventiva reports 2025 First Quarter Financial Information¹

Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues.

Inventiva reports 2025 First Quarter Financial Information¹

See News Rankings

Charts implemented using Lightweight Charts™